Drug Type Small molecule drug |
Synonyms PLX 300, PLX300 |
Target |
Mechanism PPARα agonists(Peroxisome proliferator-activated receptor α agonists), Apoptosis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization Polaryx Therapeutics, Inc.Startup |
Active Organization Polaryx Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (US), Rare Pediatric Disease (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Niemann-Pick Disease, Type A | Phase 1 | US | Polaryx Therapeutics, Inc.Startup | 18 Dec 2020 |
Leukodystrophy, Globoid Cell | Phase 1 | US | Polaryx Therapeutics, Inc.Startup | 14 Nov 2020 |
Niemann-Pick Disease, Type B | Preclinical | US | Polaryx Therapeutics, Inc.Startup | 10 Nov 2020 |
Sandhoff Disease | Preclinical | US | Polaryx Therapeutics, Inc.Startup | 10 Nov 2020 |
Tay-Sachs Disease | Preclinical | US | Polaryx Therapeutics, Inc.Startup | 04 Nov 2020 |